Skip to content

Workshop: Assessing Genomic Sequencing Information for Health Care Decision Making

January 24, 2014

The Institute of Medicine (IOM) is a nonprofit independent organization, that works outside of the US government to provide “unbiased and authoritative advice to decision makers and the public.” IOM is founded in 1970 and is the health arm of the National Academy of Sciences. IOM’s purpose:

“is to help those in government and the private sector make informed health decisions by providing evidence upon which they can rely… Many of the studies that the IOM undertakes begin as specific mandates from Congress; still others are requested by federal agencies and independent organizations…”

Genomic sequencing, in simplest terms, is the sequencing of the whole genome of an organism. Genomic sequencing gives researchers and scientists the capability to both read and interpret genetic information found in the DNA of humans. With today’s technology, both the speed and the price of genomic sequencing have improved greatly. According to a recent online article, Illumina’s new sequencing machine can read a human genome for $1,000 and in 3 days, 16 human genomes can be sequenced. Genomic sequencing is a great tool for rare diseases – helping with the genetic identification and diagnosis, and provides for the ability for the development of targeted or personalized therapeutic treatments.

The success of the sequencing of the human genome over the past 10 years is helping with the development of treatments for genetic-based targeted therapy for diseases. Large-scale genome sequencing is starting to enter clinical practice for determining patient treatment options. Best practices for evaluating available evidence for this type of clinical decision making is needed. To identify best practices requires understanding how different stakeholders gather and evaluate existing genomic evidence to develop guidelines and make clinical and reimbursement decisions.

An upcoming February IOM meeting will be of interest to patient advocates, pharmaceutical industry professionals, scientists, researchers, and academics involved in the rare disease and orphan drug space.

IOM’s Roundtable on Translating Genomic-Based Research for Health will host a public Workshop, scheduled for February 3, 2014, 8:30 A.M. – 5:45 P.M in Washington, DC. The Workshop will gather and evaluate how evidence for genomic applications is used for:

•   Clinical decision-making

•   Reimbursement decisions

•   Guideline development.

For additional information about this Workshop:

•   Description

•   Agenda

•   Registration.

Please Note: “DNA Double Helix With Data” by Jonathan Bailey, courtesy of NHGRI.

Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: